Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study

Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite’s Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. The data provided from the analysis by RPPA will be used to help oncologists select from multiple treatment options where no current guidance is available.

Read more at globenewswire.com